Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 33Breast Neoplasms 26Triple Negative Breast Neoplasms 17Prostatic Neoplasms 16Fallopian Tube Neoplasms 11Neoplasms 9Fanconi Anemia, Complementation Group D1 7Endometrial Neoplasms 7Pancreatic Neoplasms 6Glioma 6Carcinoma, Ovarian Epithelial 6Stomach Neoplasms 5Small Cell Lung Carcinoma 5Sarcoma 5Neoplasm Metastasis 5Cholangiocarcinoma 5Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Lymphoma, Non-Hodgkin 4Carcinoma, Non-Small-Cell Lung 4Advanced Breast Cancer 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Osteosarcoma 3Lung Neoplasms 3Glioblastoma 3Colorectal Neoplasms 3Carcinosarcoma 3Carcinoma, Renal Cell 3Wilms Tumor 2

Interventions

olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Solid Neoplasms × olaparib × Clear all
NCT03742895 2026-05-15

MK-7339-002

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
329 enrolled

Advanced Solid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡